Aufklappen
Schliessen
- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten |
|---|---|
| Fr | Bausch Health signs stalking horse agreement to buy Synergy Pharmaceuticals |
| Fr | Novartis gets EC approval for self-administration of Xolair across all indications |
| Fr | AMAG Pharmaceuticals to buy biopharmaceutical firm Perosphere |
| Do | X-Chem, Almirall forge dermatology-focused drug discovery alliance |
| Do | Weizmann researchers discover new neural mechanism underlying anxiety |
| Do | Janssen's Tremfya meets primary endpoint in phase 3 psoriasis trial |
| Mi | Schrödinger, TB Alliance collaborate to advance tuberculosis drug discovery |
| Mi | Versant Ventures launches new biotech firm Black Diamond Therapeutics |
| Mi | Circassia to acquire full US rights of AstraZeneca's COPD treatment Tudorza |
| Di | Alnylam, Silence Therapeutics settle patent dispute |
| Di | e-therapeutics, Novo Nordisk enter into research collaboration agreement |
| Di | PCI expands cold chain storage capabilities at UK site |
| Di | BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers |
| Mo | French pharma firm Cristers selects Adents Prodigi serialisation solution |
| Mo | Eisai, UCL to launch phase I trials of E2814 for Alzheimer's disease |
| Mo | AstraZeneca's Imfinzi fails to improve OS in head and neck cancer trial |
| 07.12. | AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma |
| 06.12. | Mereo BioPharma, OncoMed Pharmaceuticals proposes merger deal |
| 06.12. | Tris Pharma recalls infants' liquid Ibuprofen in US |
| 06.12. | Biopharmaceutical firm UCB to invest £1bn in UK for research and development |
| 05.12. | Novartis initiates phase III trials of ligelizumab in urticaria |
| 05.12. | Ixico secures expanded contract from major biopharmaceutical firm |
| 05.12. | J&J's Darzalex reduces disease progression in multiple myeloma study |
| 04.12. | Momenta revises regulatory strategy for proposed Humira biosimilar |
| 04.12. | TRIGR Therapeutics, ABL Bio sign license agreement for bispecific antibody candidate |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage